Immatics (IMTX) Debt to Equity (2020 - 2022)

Immatics' (IMTX) quarterly Debt to Equity came in at $0.18 in Q3 2022, down 76.33% year-on-year from $0.75 in Q3 2021, and up 56.45% quarter-over-quarter from $0.11 in Q2 2022.

Immatics (IMTX) Debt to Equity (2020 - 2022) Analysis & Trends

Immatics has disclosed Debt to Equity across 3 years of filings, most recently posting $0.18 for Q3 2022.

  • Debt to Equity for Q3 2022 came in at $0.18, down 76.33% year-over-year; the trailing twelve-month figure through Sep 2022 was $0.18 (down 76.33% YoY), and the FY2021 annual result was $1.16, up 3597.17% from the prior year.
  • Debt to Equity came in at $0.18 for Q3 2022 at Immatics, up from $0.11 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.16 in Q4 2021 to a low of $0.03 in Q4 2020.
  • The 3-year median for Debt to Equity is $0.21 (2021), against an average of $0.37.
  • Across the five-year window, Debt to Equity soared 3597.17% in 2021 and plunged 76.33% in 2022, its largest moves.
  • Immatics' Debt to Equity stood at $0.03 in 2020, then jumped by 3597.17% to $1.16 in 2021, then sank by 84.73% to $0.18 in 2022.
  • The last three Debt to Equity figures came in at $0.18 (Q3 2022), $0.11 (Q2 2022), and $0.1 (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Immatics 14.67 Bn 14.67 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2022 0.18
Jun 30, 2022 0.11
Mar 31, 2022 0.10
Dec 31, 2021 1.16
Sep 30, 2021 0.75
Jun 30, 2021 0.37
Mar 31, 2021 0.24
Dec 31, 2020 0.03